TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-09 and is reviewed periodically as new material appears.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
The roots of modern bird collections are found in the 18th- and 19th-century explorations of Europeans intent on documenting global plant and animal diversity. It was a fashion to collect and display natural curiosities in Victorian England. Some wealthy cabinet naturalists were able to amass large collections using networks of field collectors. These early collections were not intended for scientific study and the collectors gave importance to aesthetics rather than scientific value. It grew into a more scientific pursuit much later.
A Cochrane systematic review in 2011 showed that treatment with Sulphonylurea did not improve control of glucose levels more than insulin at 3 nor 12 months of treatment. The review found evidence that treatment with Sulphonylurea could lead to earlier insulin dependence, with 30% of cases requiring insulin at 2 years. When studies measured fasting C-peptide, no intervention influenced its concentration, but insulin maintained concentration better than Sulphonylurea. The authors also examined a study utilizing Glutamic Acid Decarboxylase formulated with aluminium hydroxide (GAD65), which showed improvements in C-peptide levels that were maintained for 5 years. Vitamin D with insulin also demonstrated steady fasting C-peptide levels in the vitamin group, with the same levels declining in the insulin-only group at a 12-month follow-up. One study examining the effects of insulin together with Chinese remedies on fasting C-peptide on a 3-month follow-up did not show a difference compared to insulin alone. However, the studies available to be included in this review presented considerable flaws in quality and design.
Actin is a family of globular multi-functional proteins that form microfilaments in the cytoskeleton, and the thin filaments in muscle fibrils. It is found in essentially all eukaryotic cells, where it may be present at a concentration of over 100 μM; its mass is roughly 42 kDa, with a diameter of 4 to 7 nm. An actin protein is the monomeric subunit of two types of filaments in cells: microfilaments, one of the three major components of the cytoskeleton, and thin filaments, part of the contractile apparatus in muscle cells. It can be present as either a free monomer called G-actin (globular) or as part of a linear polymer microfilament called F-actin (filamentous), both of which are essential for the cellular functions of mobility and the contraction of cells during cell division. Actin participates in many important cellular processes, including muscle contraction, cell motility, cell division and cytokinesis, vesicle and organelle movement, cell signaling, and the establishment and maintenance of cell junctions and cell shape. Many of these processes are mediated by extensive and intimate interactions of actin with cellular membranes. In vertebrates, three main groups of actin isoforms, alpha, beta, and gamma have been identified. The alpha actins, found in muscle tissues, are a major constituent of the contractile apparatus. The beta and gamma actins coexist in most cell types as components of the cytoskeleton, and as mediators of internal cell motility.
=== Studies of enzyme mechanism === Many proteins require the simultaneous or sequential binding of multiple substrates, cofactors, and/or allosteric effectors. Thermofluor studies of molecules that bind to active site subsites, cofactor sites, or allosteric binding sites can help elucidate specific features of enzyme mechanism that can be important in the design of effective drug screening campaigns and in characterizing novel inhibitory mechanisms.
Saint Paul Public Schools Solid phase peptide synthesis Solution precursor plasma spray Steam Powered Preservation Society South Park Primary School, a primary school in London, United Kingdom Scandinavian Plant Physiology Society Social Psychological and Personality Science, a quarterly academic journal for social and personality psychology-related topics Spectral Parameter Power Series, a method for solving Sturm–Liouville equations Super Proton-Antiproton Collider (SppS), a modification of the Super Proton Synchrotron, an accelerator at CERN
Sources: en.wikipedia.org
=== Controversies === The FDA authorized use of injectable naltrexone (Vivitrol) for opioid addiction using a single study that was led by Evgeny Krupitsky at Bekhterev Research Psychoneurological Institute, St Petersburg State Pavlov Medical University, St Petersburg, Russia, a country where opioid agonists such as methadone and buprenorphine are not available. The study was a "double-blind, placebo-controlled, randomized", 24-week trial running "from July 3, 2008, through October 5, 2009" with "250 patients with opioid dependence disorder" at "13 clinical sites in Russia" on the use of injectable naltrexone (XR-NTX) for opioid dependence. The study was funded by the Boston-based biotech Alkermes firm which produces and markets naltrexone in the United States. Critics charged that the study violated ethical guidelines since it compared the formulation of naltrexone not to the best available, evidence-based treatment (methadone or buprenorphine), but to a placebo. Further, the trial did not follow patients who dropped out of the trial to evaluate subsequent risk of fatal overdose, a major health concern. Subsequent trials in Norway and the US did compare injectable naltrexone to buprenorphine and found them to be similar in outcomes for patients willing to undergo the withdrawal symptoms required before naltrexone administration. Nearly 30% of patients in the US trial did not complete induction.
Nine men have portrayed Biden on Saturday Night Live, starting with Kevin Nealon in 1991. Jason Sudeikis portrayed Biden during the 2008 election and reprised the role many times. During the 2020 election, Biden was played by John Mulaney, Alex Moffat, Mikey Day, Woody Harrelson, and Jim Carrey. In 2024, Dana Carvey played the role. In 2016, Greg Kinnear portrayed Biden in the HBO television film Confirmation, about the Clarence Thomas Supreme Court nomination hearings. Biden appears in episodes of Parks and Recreation during his time as vice president. He appears as himself in a 2016 episode of Law & Order: SVU. The Onion ran a series of articles about a fictionalized Biden.
==== Benzamides ==== Amisulpride (Socian) ‡ – Selective dopamine antagonist. Higher doses (greater than 400 mg) act upon post-synaptic dopamine receptors resulting in a reduction in the positive symptoms of schizophrenia, such as psychosis. Lower doses, however, act upon dopamine autoreceptors, resulting in increased dopamine transmission, improving the negative symptoms of schizophrenia. Lower doses of amisulpride have also been shown to have antidepressant and anxiolytic effects in non-schizophrenic patients, leading to its use in dysthymia and social phobias. Nemonapride † – Used in Japan. Remoxipride # – Has a risk of causing aplastic anaemia and, hence, has been withdrawn from the market worldwide. It has also been found to possess relatively low (virtually absent) potential to induce hyperprolactinaemia and extrapyramidal symptoms, likely attributable to its comparatively weak binding to (and, hence, rapid dissociation from) the D2 receptor. Sultopride – An atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist.
== Biological effects == Alloxan is a toxic glucose analogue, which selectively destroys insulin-producing cells in the pancreas (that is, beta cells) when administered to rodents and many other animal species. This causes an insulin-dependent diabetes mellitus (called "alloxan diabetes") in these animals, with characteristics similar to type 1 diabetes in humans. Alloxan is selectively toxic to insulin-producing pancreatic beta cells because it preferentially accumulates in beta cells through uptake via the GLUT2 glucose transporter. Studies suggest alloxan does not cause diabetes in humans. Others found a significant difference in alloxan plasma levels in children with and without type 1 diabetes.
=== Airspace restrictions === At the direction of the US Department of Defense, the US Federal Aviation Administration (FAA) banned flights in an area around Ceiba, Puerto Rico, for "special security reasons" from 1 November 2025 to 31 March 2026. On 21 November, the FAA urged airlines flying over Venezuela at any altitude to exercise caution due to the "worsening security situation and heightened military activity in or around Venezuela". Increased GPS interference, linked to military action by both the US and Venezuela, made flight dangerous; by 25 November, at least eleven airlines had temporarily suspended flights to Venezuela. After threatening to permanently suspend the clearances of airlines that did not resume flights within 48 hours, on 26 November, Venezuela revoked the licenses of six airlines they said had "joined actions of state terrorism promoted by the United States". While Venezuela has authority over its airspace, on 29 November, Trump announced that airspace over the country should be considered entirely closed, days after he stated that the US would begin to strike land targets "very soon". The Washington Post stated that "such a move is sometimes a first step ahead of airstrikes"; while Trump cannot legally close Venezuela's airspace and he did not impose a no-fly zone, the "threat ... might be enough to prompt commercial airlines to halt flights over Venezuela". Venezuelan officials condemned Trump's statement as a "colonialist threat", stating that Venezuela rejects "orders, threats, or interference from any foreign power".
Sources: en.wikipedia.org
== Education == Cooks received Bachelor of Science and Master of Science degrees from the University of Natal in South Africa in 1961 and 1963, respectively. He received a Ph.D. from the University of Natal in 1965 and a second Ph.D. from Cambridge University in 1967, where he worked with Peter Sykes. He then did post-doctoral work at Cambridge with Dudley Williams.
=== HIV/AIDS === Baricitinib has been investigated for its potential to reduce the HIV reservoir and chronic inflammation in people infected with HIV. Preclinical studies in humanized mice and non-human primates have demonstrated that the drug can penetrate the blood-brain barrier and reach therapeutic concentrations in the central nervous system (CNS). In these models, baricitinib was associated with a reduction in cellular activation markers, lower frequencies of infected macrophages in the brain, and improvements in HIV-associated behavioral deficits. Research suggests that by blocking the JAK-STAT signaling pathway, the drug may limit the survival of infected cells and prevent the reseeding of viral reservoirs in sanctuary sites like the CNS, which are often poorly reached by standard antiretroviral therapy (ART). As of 2025, baricitinib is currently being evaluated in multiple Phase II clinical trials to assess its safety and efficacy as an adjunctive therapy to ART. One primary area of focus is its ability to decrease or clear the CNS reservoir, with ongoing trials monitoring changes in cerebrospinal fluid (CSF) viral DNA and neurocognitive function. Additional studies are examining its impact on systemic inflammation, cell survival pathways, and the delay of viral rebound during monitored treatment interruptions.
24 October – Data from National Records of Scotland indicates there were 24,427 deaths in Scotland between December 2022 and March 2023, 11% higher than the previous year, and the highest number since the winter of 1989–90. Jason Grant, who was hired as Scotland's first period dignity officer in 2022 but then lost the post after it was discontinued amid controversy over the appointment of a male, has settled with his employers out of court for a case of sex discrimination. 24 October – Anas Sarwar, the leader of Scottish Labour, accuses Israel of a "clear breach" of international law in Gaza and says there is "no justification for the withholding of essential supplies" from the people of Gaza. His comments come after a number of Scottish Labour resignations by officials who disagree with Keir Starmer's stance on the conflict. 25 October – Christopher McGowan is sentenced to life imprisonment with a minimum term of 23 years for the murder of his girlfriend of eight weeks, Claire Inglis, which took place after he was bailed to her address. 26 October – The Times reports that WhatsApp messages sent by National Clinical Director Jason Leitch cannot be handed to the UK or Scottish COVID-19 inquiries because he deleted them on a daily basis. Scottish band Young Fathers win the 2023 Scottish Album of the Year Award for their fourth album, Heavy Heavy. Scottish Labour leader Anas Sarwar breaks with the stance of Labour's leader, Sir Keir Starmer, on the Israel–Hamas conflict by calling for a ceasefire in Gaza.
=== Aviation === AEG C.VIII, a World War I German armed reconnaissance aircraft AGO C.VIII, a World War I German reconnaissance aircraft Cierva C.8, a 1926 Spanish experimental autogyro De Havilland Canada C-8 Buffalo, a military transport aircraft of the 1960s Fairchild C-8, a military transport aircraft of the 1930s Fokker C.VIII, a 1928 Dutch reconnaissance aircraft Chicago Express Airlines (defunct) IATA code
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.